News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,500 Results
Type
Article (41092)
Company Profile (279)
Press Release (678123)
Multimedia
Podcasts (79)
Webinars (17)
Section
Business (205137)
Career Advice (2020)
Deals (35581)
Drug Delivery (107)
Drug Development (81577)
Employer Resources (173)
FDA (16384)
Job Trends (14990)
News (347031)
Policy (32736)
Tag
Academia (2585)
Academic (1)
Accelerated approval (23)
Adcomms (24)
Allergies (130)
Alliances (49751)
ALS (157)
Alzheimer's disease (1621)
Antibody-drug conjugate (ADC) (262)
Approvals (16555)
Artificial intelligence (459)
Autoimmune disease (116)
Automation (33)
Bankruptcy (361)
Best Places to Work (11694)
BIOSECURE Act (20)
Biosimilars (175)
Biotechnology (183)
Bladder cancer (142)
Brain cancer (51)
Breast cancer (574)
Cancer (4356)
Cardiovascular disease (357)
Career advice (1702)
Career pathing (34)
CAR-T (261)
CDC (45)
Celiac Disease (1)
Cell therapy (679)
Cervical cancer (34)
Clinical research (69103)
Collaboration (1452)
Company closure (4)
Compensation (1023)
Complete response letters (46)
COVID-19 (2708)
CRISPR (82)
C-suite (682)
Cystic fibrosis (135)
Data (5620)
Decentralized trials (2)
Denatured (28)
Depression (110)
Diabetes (453)
Diagnostics (6607)
Digital health (38)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (215)
Drug pricing (168)
Drug shortages (28)
Duchenne muscular dystrophy (208)
Earnings (89831)
Editorial (50)
Employer branding (21)
Employer resources (151)
Events (116944)
Executive appointments (939)
FDA (19086)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1321)
Gene editing (180)
Generative AI (38)
Gene therapy (534)
GLP-1 (912)
Government (4632)
Grass and pollen (8)
Guidances (375)
Healthcare (18940)
HIV (47)
Huntington's disease (38)
IgA nephropathy (75)
Immunology and inflammation (247)
Immuno-oncology (34)
Indications (76)
Infectious disease (2949)
Inflammatory bowel disease (183)
Inflation Reduction Act (15)
Influenza (101)
Intellectual property (209)
Interviews (315)
IPO (16647)
IRA (50)
Job creations (3651)
Job search strategy (1429)
Kidney cancer (15)
Labor market (79)
Layoffs (546)
Leadership (28)
Legal (7943)
Liver cancer (87)
Longevity (12)
Lung cancer (606)
Lymphoma (347)
Machine learning (38)
Management (59)
Manufacturing (662)
MASH (151)
Medical device (13684)
Medtech (13720)
Mergers & acquisitions (19882)
Metabolic disorders (1131)
Multiple sclerosis (140)
NASH (16)
Neurodegenerative disease (277)
Neuropsychiatric disorders (69)
Neuroscience (2693)
NextGen: Class of 2025 (6536)
Non-profit (4512)
Now hiring (60)
Obesity (524)
Opinion (247)
Ovarian cancer (149)
Pain (166)
Pancreatic cancer (188)
Parkinson's disease (252)
Partnered (31)
Patents (444)
Patient recruitment (383)
Peanut (55)
People (58734)
Pharmaceutical (65)
Pharmacy benefit managers (26)
Phase I (21551)
Phase II (30425)
Phase III (22667)
Pipeline (3686)
Policy (263)
Postmarket research (2568)
Preclinical (9215)
Press Release (66)
Prostate cancer (211)
Psychedelics (42)
Radiopharmaceuticals (258)
Rare diseases (699)
Real estate (5970)
Recruiting (69)
Regulatory (23909)
Reports (51)
Research institute (2386)
Resumes & cover letters (351)
Rett syndrome (22)
RNA editing (13)
RSV (73)
Schizophrenia (135)
Series A (218)
Series B (166)
Service/supplier (11)
Sickle cell disease (91)
Special edition (20)
Spinal muscular atrophy (153)
Sponsored (40)
Startups (3626)
State (2)
Stomach cancer (16)
Supply chain (96)
Tariffs (80)
The Weekly (49)
Vaccines (953)
Venture capital (71)
Weight loss (340)
Women's health (72)
Worklife (17)
Date
Last 7 days (637)
Last 30 days (2361)
Last 365 days (30311)
2025 (29477)
2024 (35361)
2023 (40214)
2022 (51335)
2021 (55870)
2020 (54240)
2019 (46649)
2018 (35127)
2017 (32208)
2016 (31570)
2015 (37635)
2014 (31385)
2013 (26428)
2012 (28651)
2011 (29330)
2010 (27397)
Location
Africa (735)
Alabama (82)
Alaska (7)
Arizona (288)
Arkansas (13)
Asia (39129)
Australia (6409)
California (10337)
Canada (3078)
China (962)
Colorado (433)
Connecticut (445)
Delaware (303)
Europe (84533)
Florida (1529)
Georgia (328)
Hawaii (2)
Idaho (61)
Illinois (787)
India (54)
Indiana (485)
Iowa (20)
Japan (358)
Kansas (122)
Kentucky (36)
Louisiana (24)
Maine (70)
Maryland (1307)
Massachusetts (7484)
Michigan (299)
Minnesota (581)
Mississippi (5)
Missouri (118)
Montana (31)
Nebraska (26)
Nevada (111)
New Hampshire (73)
New Jersey (2794)
New Mexico (29)
New York (2756)
North Carolina (1351)
North Dakota (8)
Northern California (4959)
Ohio (302)
Oklahoma (20)
Oregon (38)
Pennsylvania (2116)
Puerto Rico (19)
Rhode Island (45)
South America (1102)
South Carolina (58)
South Dakota (1)
Southern California (3994)
Tennessee (161)
Texas (1588)
United States (36986)
Utah (306)
Vermont (1)
Virginia (240)
Washington D.C. (78)
Washington State (845)
West Virginia (4)
Wisconsin (89)
Wyoming (2)
719,500 Results for "triumvira immunologics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium
January 27, 2025
·
2 min read
Press Releases
Triumvira Immunologics to Present Updated Clinical Data at the 2025 SITC Spring Scientific, Cellular Therapy and Solid Tumors Conference
March 12, 2025
·
3 min read
Deals
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
BioSpace and guests from Halia Therapeutics, Triumvira Immunologics and the Alzheimer’s Drug Discovery Foundation discuss alternative financing strategies to consider for 2024. Listen now.
January 4, 2024
·
1 min read
·
BioSpace Insights
Immunology and inflammation
Biogen Grows Immunology Pipeline With Vanqua’s Anti-Inflammatory Molecule
The $70 million upfront deal adds to a portfolio of drugs Biogen has been growing in various immunological conditions since 2024.
October 24, 2025
·
2 min read
·
Dan Samorodnitsky
Triumvira Immunologics to Present Clinical Data at the 2024 ASCO Gastrointestinal Cancers Symposium
Triumvira Immunologics today announced that it will present two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, California, from January 18-20, 2024.
December 19, 2023
·
3 min read
Press Releases
Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2 in Solid Tumors
October 15, 2024
·
4 min read
Earnings
AbbVie’s Immunology Dyad Dominates Again in Q3
Skyrizi and Rinvoq made nearly $7 billion combined, almost half of the company’s income for the quarter alone.
October 31, 2025
·
2 min read
·
Dan Samorodnitsky
Triumvira Immunologics to Present New Clinical and Preclinical Data on its TAC-T Cell Technology at SITC 2023 Annual Meeting
Triumvira Immunologics today announced that it will participate with one oral presentation and four posters at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, California, from November 1-5.
October 30, 2023
·
4 min read
Drug Development
Triumvira Immunologics Announces First Patient Dosed in Phase I/II Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors
Triumvira Immunologics today announced that the first patient has been dosed in its TACTIC-3 trial, a Phase I/II study, (NCT05862324) investigating the safety and efficacy of autologous TAC-T cell asset, TAC101-CLDN18.2, targeting Claudin 18.2+ solid tumors.
February 5, 2024
·
3 min read
Business
Triumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences Executives
Triumvira Immunologics today announced the strengthening of its leadership team with the appointments of Mr. Robert Williamson as President, Chief Operating Officer and member of the Board of Directors, Mr. Jeffrey Erickson as VP of Business Development, and Mr. Chris Murray as VP of Human Resources.
July 20, 2023
·
4 min read
1 of 71,950
Next
